Shares of Hookipa Pharma Inc (NASDAQ:HOOK) have received an average rating of “Buy” from the seven brokerages that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $19.00.
A number of research analysts recently issued reports on HOOK shares. Zacks Investment Research lowered Hookipa Pharma from a “hold” rating to a “sell” rating in a report on Tuesday, October 15th. HC Wainwright initiated coverage on Hookipa Pharma in a research report on Friday, September 27th. They issued a “buy” rating and a $15.00 price target for the company. Royal Bank of Canada reiterated a “buy” rating and issued a $23.00 price target on shares of Hookipa Pharma in a research report on Wednesday, August 14th. Finally, ValuEngine upgraded Hookipa Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, October 1st.
Shares of HOOK traded up $0.20 during trading hours on Tuesday, reaching $8.41. 14,500 shares of the company’s stock traded hands, compared to its average volume of 18,460. The company has a debt-to-equity ratio of 0.08, a quick ratio of 8.69 and a current ratio of 8.69. Hookipa Pharma has a twelve month low of $6.06 and a twelve month high of $14.76. The stock has a fifty day simple moving average of $7.60.
Several large investors have recently added to or reduced their stakes in the stock. Artal Group S.A. acquired a new stake in Hookipa Pharma during the 2nd quarter worth about $7,636,000. Samsara BioCapital LLC acquired a new stake in Hookipa Pharma during the 2nd quarter worth about $3,569,000. Tower Research Capital LLC TRC acquired a new stake in Hookipa Pharma during the 2nd quarter worth about $40,000. Hillhouse Capital Advisors LTD. acquired a new stake in Hookipa Pharma during the 2nd quarter worth about $1,923,000. Finally, Northern Trust Corp acquired a new stake in shares of Hookipa Pharma during the 2nd quarter valued at about $72,000. Institutional investors and hedge funds own 30.36% of the company’s stock.
About Hookipa Pharma
HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Further Reading: What is an investor looking for in an SEC filing?
Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.